Physician profile
John J Marsella
NPI 1326027236
$7,676.72
in general payments reported to CMS, 2019-2025
30 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,079 · 2020: $320 · 2021: $1,732 · 2022: $373 · 2023: $220 · 2024: $1,851 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406 · Travel and Lodging: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.79 |
| Travel and Lodging | $767.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,700.75 | 2019-2025 | Proclaim, Eterna, Octrode |
| Mml US, INC. | $1,317.51 | 2024-2025 | Reactiv8 |
| Boston Scientific Corporation | $576.98 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Na |
| Collegium Pharmaceutical, INC. | $309.59 | 2022-2025 | Belbuca, Xtampza |
| Forte Bio-Pharma LLC | $239.88 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Si-Bone, INC. | $175.03 | 2020-2021 | |
| Nevro Corp. | $167.89 | 2022-2024 | Senza |
| Medtronic USA, INC. | $156.66 | 2019-2020 | |
| Stimwave Technologies Incorporated | $155.86 | 2019-2020 | |
| Curonix LLC | $131.52 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Arbor Pharmaceuticals, INC. | $101.78 | 2021-2022 | |
| Baxter Healthcare | $78.80 | 2019-2020 | |
| Ibsa Pharma INC. | $78.21 | 2024-2025 | Licart, Tirosint, Flector |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.85 | 2022 | |
| Grt US Holding, INC. | $45.00 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $41.80 | 2024-2025 | |
| Spr Therapeutics, INC | $40.32 | 2024 | Sprint Pns System |
| Kls-Martin L.P. | $38.72 | 2021 | |
| Scilex Pharmaceuticals INC. | $35.84 | 2024 | |
| Flowonix Medical Incorporated | $35.67 | 2019-2020 | |
| Nalu Medical, INC. | $35.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.86 | 2022-2023 | Seglentis |
| Almatica Pharma LLC | $21.42 | 2022 | |
| Nuvasive, INC. | $19.19 | 2019 | |
| Abbvie INC. | $17.15 | 2025 | |
| Biotronik Nro, INC. | $16.87 | 2025 | Prospera |
| Idorsia Pharmaceuticals US INC | $15.77 | 2023 | Quviviq |
| Averitas Pharma INC. | $15.65 | 2024 | Qutenza |
| Daiichi Sankyo INC. | $12.94 | 2019 | |
| Biodelivery Sciences International, INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marsella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.